Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $4.1 million.

  • Crinetics Pharmaceuticals' Non-Current Deffered Revenue fell 2088.55% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 2088.55%. This contributed to the annual value of $4.7 million for FY2024, which is 96.84% down from last year.
  • Crinetics Pharmaceuticals' Non-Current Deffered Revenue amounted to $4.1 million in Q3 2025, which was down 2088.55% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Non-Current Deffered Revenue registered a high of $7.2 million during Q1 2022, and its lowest value of $2000.0 during Q4 2021.
  • Over the past 5 years, Crinetics Pharmaceuticals' median Non-Current Deffered Revenue value was $4.7 million (recorded in 2024), while the average stood at $4.1 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first plummeted by 9130.43% in 2021, then soared by 30495000.0% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $2000.0 in 2021, then surged by 304950.0% to $6.1 million in 2022, then fell by 22.14% to $4.8 million in 2023, then dropped by 0.97% to $4.7 million in 2024, then dropped by 12.63% to $4.1 million in 2025.
  • Its Non-Current Deffered Revenue stands at $4.1 million for Q3 2025, versus $4.0 million for Q2 2025 and $4.3 million for Q1 2025.